癌症研究
PI3K/AKT/mTOR通路
蛋白激酶B
磷酸化
细胞生物学
卵巢癌
激酶
生物
酪氨酸激酶
化学
信号转导
癌症
遗传学
作者
Yanchun Zhang,Xuexue Xiong,Qi Zhu,Jiali Zhang,Shengmiao Chen,Yuetong Wang,Jian Cao,Li Chen,Linjun Hou,Xi Zhao,Piliang Hao,Jian Chen,Min Zhuang,Dake Li,Gaofeng Fan
出处
期刊:eLife
[eLife Sciences Publications Ltd]
日期:2022-05-12
卷期号:11
被引量:16
摘要
Tyrosine phosphorylation, orchestrated by tyrosine kinases and phosphatases, modulates a multi-layered signaling network in a time- and space-dependent manner. Dysregulation of this post-translational modification is inevitably associated with pathological diseases. Our previous work has demonstrated that non-receptor tyrosine kinase FER is upregulated in ovarian cancer, knocking down which attenuates metastatic phenotypes. However, due to the limited number of known substrates in the ovarian cancer context, the molecular basis for its pro-proliferation activity remains enigmatic. Here, we employed mass spectrometry and biochemical approaches to identify insulin receptor substrate 4 (IRS4) as a novel substrate of FER. FER engaged its kinase domain to associate with the PH and PTB domains of IRS4. Using a proximity-based tagging system in ovarian carcinoma-derived OVCAR-5 cells, we determined that FER-mediated phosphorylation of Tyr779 enables IRS4 to recruit PIK3R2/p85β, the regulatory subunit of PI3K, and activate the PI3K-AKT pathway. Rescuing IRS4 -null ovarian tumor cells with phosphorylation-defective mutant, but not WT IRS4 delayed ovarian tumor cell proliferation both in vitro and in vivo. Overall, we revealed a kinase-substrate mode between FER and IRS4, and the pharmacological inhibition of FER kinase may be beneficial for ovarian cancer patients with PI3K-AKT hyperactivation.
科研通智能强力驱动
Strongly Powered by AbleSci AI